Please assess the completion status of the following clinical trial:

Trial Title: Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Multiple sclerosis \[MS\] subject who was ambulatory (EDSS of ≤ 5.5)~* Exhibiting a relapsing clinical course, with or without progression (relapsing remitting, secondary progressive or progressive relapsing);~* Meeting McDonald's criteria for MS diagnosis;~* Experienced at least 1 relapse over the 1 year preceding the trial or at least 2 relapses over the 2 years preceding the trial;~* No relapse onset in the preceding 60 days prior to randomization;~* Clinically stable during the 30 days prior to randomization, without adrenocorticotrophic hormone \[ACTH\] or systemic steroid treatment.~Exclusion Criteria:~* Clinically relevant cardiovascular, hepatic, neurological, endocrine or other major systemic disease;~* Significantly impaired bone marrow function;~* Pregnant or nursing woman;~* Alcohol or drug abuse;~* Use of cladribine, mitoxantrone, or other immunosuppressant agents such as azathioprine, cyclophosphamide, cyclosporin, methotrexate or mycophenolate before enrollment;~* Any known condition or circumstance that would prevent in the investigator's opinion compliance or completion of the study;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Teriflunomide 7 mg (Type: EXPERIMENTAL): Teriflunomide 7 mg once daily for 108 weeks
- Teriflunomide 14 mg (Type: EXPERIMENTAL): Teriflunomide 14 mg once daily for 108 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (for teriflunomide) once daily for 108 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).